169 related articles for article (PubMed ID: 11979388)
1. Comparison of insulinotrophic actions of nateglinide with glibenclamide dissociated from absorption in conscious dogs.
Okamoto M; Ogihara N; Kawamura W; Ebihara S; Takiguchi K; Morita T; Uchida R; Yamaguchi J; Sakai T; Okuda Y; Hayashi Y; Arakawa Y; Kikuchi M
Metabolism; 2002 May; 51(5):575-81. PubMed ID: 11979388
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
[TBL] [Abstract][Full Text] [Related]
3. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
[TBL] [Abstract][Full Text] [Related]
4. The mechanisms underlying the unique pharmacodynamics of nateglinide.
Hu S; Boettcher BR; Dunning BE
Diabetologia; 2003 Mar; 46 Suppl 1():M37-43. PubMed ID: 12652357
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats.
Courtois P; Jijakli H; Ladriere L; Oguzhan B; Sener A; Malaisse WJ
Int J Mol Med; 2003 Jan; 11(1):105-9. PubMed ID: 12469228
[TBL] [Abstract][Full Text] [Related]
6. Insulin secretion from isolated rat islets induced by the novel hypoglycemic agent A-4166, a derivative of D-phenylalanine.
Tsukuda K; Sakurada M; Niki I; Oka Y; Kikuchi M
Horm Metab Res; 1998 Jan; 30(1):42-9. PubMed ID: 9503038
[TBL] [Abstract][Full Text] [Related]
7. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
Karara AH; Dunning BE; McLeod JF
J Clin Pharmacol; 1999 Feb; 39(2):172-9. PubMed ID: 11563410
[TBL] [Abstract][Full Text] [Related]
8. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
Malaisse WJ
Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
[TBL] [Abstract][Full Text] [Related]
10. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Kikuchi M
Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
McLeod JF
Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
[TBL] [Abstract][Full Text] [Related]
12. A novel enhancer of insulinotrophic action by high glucose (JTT-608) stimulates insulin secretion from pancreatic beta-cells via a new cellular mechanism.
Itabashi N; Okada K; Muto S; Fujita N; Ohta T; Miyazaki Ji ; Asano Y; Saito T
J Pharmacol Exp Ther; 2001 Jun; 297(3):953-60. PubMed ID: 11356916
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats.
Takanohashi T; Arisaka H; Ubukata K; Hayashi M; Yamada Y
Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):9-15. PubMed ID: 22012638
[TBL] [Abstract][Full Text] [Related]
14. [Structures and mechanisms for non SU insulin secretagogues].
Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():362-70. PubMed ID: 12387019
[No Abstract] [Full Text] [Related]
15. Insulin exocytosis in Goto-Kakizaki rat beta-cells subjected to long-term glinide or sulfonylurea treatment.
Kawai J; Ohara-Imaizumi M; Nakamichi Y; Okamura T; Akimoto Y; Matsushima S; Aoyagi K; Kawakami H; Watanabe T; Watada H; Kawamori R; Nagamatsu S
Biochem J; 2008 May; 412(1):93-101. PubMed ID: 18254725
[TBL] [Abstract][Full Text] [Related]
16. Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics.
Müller G; Hartz D; Pünter J; Okonomopulos R; Kramer W
Biochim Biophys Acta; 1994 May; 1191(2):267-77. PubMed ID: 8172912
[TBL] [Abstract][Full Text] [Related]
17. Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action.
Hu S
Eur J Pharmacol; 2002 May; 442(1-2):163-71. PubMed ID: 12020694
[TBL] [Abstract][Full Text] [Related]
18. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.
Ikenoue T; Okazaki K; Fujitani S; Tsuchiya Y; Akiyoshi M; Maki T; Kondo N
Biol Pharm Bull; 1997 Apr; 20(4):354-9. PubMed ID: 9145209
[TBL] [Abstract][Full Text] [Related]
19. Effects of D-phenylalanine-derivative hypoglycemic agent A-4166 on pancreatic alpha- and beta-cells: comparative study with glibenclamide.
Hirose H; Maruyama H; Seto Y; Ito K; Fujita T; Dan K; Kanda N; Saruta T; Kato R
Pharmacology; 1995 Mar; 50(3):175-81. PubMed ID: 7746834
[TBL] [Abstract][Full Text] [Related]
20. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
Kalbag JB; Walter YH; Nedelman JR; McLeod JF
Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
